- Home
- AMST vs NEUP Comparison
AMST vs NEUP Comparison
Compare AMST & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMST
- NEUP
- Stock Information
- Founded
- AMST 2017
- NEUP 1996
- Country
- AMST United States
- NEUP United States
- Employees
- AMST N/A
- NEUP N/A
- Industry
- AMST Computer Software: Prepackaged Software
- NEUP
- Sector
- AMST Technology
- NEUP
- Exchange
- AMST Nasdaq
- NEUP Nasdaq
- Market Cap
- AMST 9.5M
- NEUP 9.3M
- IPO Year
- AMST 2020
- NEUP N/A
- Fundamental
- Price
- AMST $2.74
- NEUP $6.65
- Analyst Decision
- AMST
- NEUP Strong Buy
- Analyst Count
- AMST 0
- NEUP 1
- Target Price
- AMST N/A
- NEUP $21.00
- AVG Volume (30 Days)
- AMST 3.4M
- NEUP 24.5K
- Earning Date
- AMST 05-15-2025
- NEUP 05-20-2025
- Dividend Yield
- AMST N/A
- NEUP N/A
- EPS Growth
- AMST N/A
- NEUP N/A
- EPS
- AMST N/A
- NEUP 0.00
- Revenue
- AMST $82,544.00
- NEUP $15,662,715.00
- Revenue This Year
- AMST N/A
- NEUP N/A
- Revenue Next Year
- AMST N/A
- NEUP N/A
- P/E Ratio
- AMST N/A
- NEUP $2.14
- Revenue Growth
- AMST N/A
- NEUP N/A
- 52 Week Low
- AMST $2.00
- NEUP $2.90
- 52 Week High
- AMST $6.27
- NEUP $126.00
- Technical
- Relative Strength Index (RSI)
- AMST 52.51
- NEUP N/A
- Support Level
- AMST $2.83
- NEUP N/A
- Resistance Level
- AMST $3.28
- NEUP N/A
- Average True Range (ATR)
- AMST 0.35
- NEUP 0.00
- MACD
- AMST -0.00
- NEUP 0.00
- Stochastic Oscillator
- AMST 30.44
- NEUP 0.00
About AMST Amesite Inc.
Amesite Inc is an artificial intelligence-driven platform and course designer that rapidly provides customized, high-performance and scalable online products for schools and businesses. The company helps educational institutions and businesses improve learning as their technology partner, delivering a disruptive technology driven by AI and offers a constellation of services that help partners implement new programs, and improve existing ones. Its customers are Enterprises, universities, and K-12 schools.
About NEUP Neuphoria Therapeutics Inc. Common Stock
Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.